chimeric antigen receptor-T cell therapy
Mayo Clinic researchers are collaborating to develop CAR-T cell therapy for solid tumors in thyroid cancer.
After Sylvester Pinckney's lymphoma returned, chimeric antigen receptor-T cell therapy at Mayo Clinic put his cancer back in remission.
After receiving CAR-T cell therapy at Mayo Clinic, Welsh-born John Cadwallader achieved remission and found new hope. He now receives care in the U.K. and is monitored by Mayo in the U.S. and London.
Dr. Mohamed Kharfan Dabaja discusses who is eligible for CAR-T cell therapy, the treatment process and its potential side effects.
After receiving CAR-T cell therapy for chronic lymphocytic leukemia through a clinical trial at Mayo Clinic, Jon Stahlecker is cancer free and feeling good.
Researchers used a new immunotherapy technique that combines chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, with a cancer-killing virus to more effectively target and treat solid cancer tumors in mouse models.
Learn about CAR-T cell therapy, a personalized treatment giving hope to patients diagnosed with various lymphomas.